A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder

Abstract

As the opioid epidemic continues to grow across the United States, the number of patients requiring treatment for opioid use disorder continues to climb. Although medication-assisted treatment presents a highly effective tool that can help address this epidemic, its use has been limited. Nonetheless, with easier dosing protocols (compared to the more complex dosing required of methadone due to its long and variable half-life) and fewer prescribing limitations (may be prescribed outside the setting of federally approved clinics), the increase in buprenorphine use in the United States has been dramatic in recent years. Despite buprenorphine’s demonstrated efficacy, patient-specific factors can alter the response to the medications, which may lead to treatment failure in some patients. Clinical characteristics (sex, concurrent medications, and mental health comorbidities) as well as social determinants of health (housing status, involvement with the criminal justice system, and socioeconomic status) may impact treatment outcomes. Furthermore, a growing body of data suggests that genetic variations can alter pharmacological effects and influence therapeutic response. This review will cover the available pharmacogenomic data for the use of buprenorphine in the management of opioid use disorders. Pharmacogenomic determinants that affect opioid receptors, the dopaminergic system, metabolism of buprenorphine, and adverse events are discussed. Although much of the existing data comes from observational studies, clinical research is ongoing. Nevertheless, the development of pharmacogenomic-guided strategies has the potential to reduce opioid misuse, improve clinical outcomes, and save healthcare resources.

Pharmacogenomic Landscape of Covid-19 Therapies From Indian Population Genomes

“…This drug is also reported to have adverse effects such as hemolytic anemia, cardiomyopathy, neutropenia, gastrointestinal disturbances, retinopathy, rash and QT prolongation [ 3 ]. Metenkefalin, an investigational endogenous opioid being studied for treatment of COVID-19 is found to have 66% of function disruption as its sole metabolizing enzyme CPA6 along with one out of its two target genes ( OPRM1 ) has a potentially deleterious variant rs1799971 with an allele frequency of 40% in Indians, which is known to affect the metabolism of other opioids [ 3 , 37 ].…”

Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder

“…Pharmacogenomics is an emerging tool that could be useful for standardizing subject pools and personalizing treatment regimens. There is an indication that the presence of certain alleles can influence optimal dosage and impact the overall efficacy of buprenorphine for a given individual (87).…”

Pharmacogenomics in Pain Management: A Review of Relevant Gene-Drug Associations and Clinical Considerations

“…Although naltrexone does not undergo phase 1 metabolism via CYP isoenzymes to its active metabolite (6-β-naltrexol), this drug may affect CYP-mediated metabolism of other drugs. 103 Naltrexone metabolism to 6B-naltrexol is mediated via dihydrodiol dehydrogenase. Currently, genetic polymorphisms of the gene coding for this enzyme have not been well reported.…”